GlassScriptPhysician profile
Landen A Meeks
NPI 1326280504
$6,100.13
in general payments reported to CMS, 2019-2025
34 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $282 · 2021: $371 · 2022: $940 · 2023: $1,122 · 2024: $1,680 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,871.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,083.49 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Abbvie INC. | $745.35 | 2022-2025 | |
| Genentech USA, INC. | $712.89 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $372.81 | 2019-2025 | Eylea Hd, Eylea |
| Rxsight INC | $319.84 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $309.79 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $244.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $239.21 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $225.25 | 2022-2025 | Syfovre |
| Oyster Point Pharma, INC. | $203.82 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $196.37 | 2022 | |
| Ocular Therapeutix, INC. | $176.26 | 2023-2024 | Dextenza |
| Abbott Laboratories | $166.44 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $161.33 | 2022-2024 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $113.13 | 2023-2025 | Xiidra, Vyzulta, Miebo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $104.35 | 2022-2024 | Byooviz |
| Coopervision INC. | $86.50 | 2023 | Myday Contact Lens |
| Astellas Pharma US INC | $79.56 | 2024-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $77.00 | 2019-2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $69.15 | 2023-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $55.44 | 2025 | Xdemvy |
| Dompe US, INC. | $53.99 | 2024-2025 | Oxervate |
| New World Medical,INC. | $49.87 | 2024-2025 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Aerie Pharmaceuticals, INC. | $44.10 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $31.75 | 2025 | Iluvien |
| Rayner Intraocular Lenses Limited | $29.41 | 2024 | Rayone Emv, Rayone Aspheric, Omidria |
| Shire North American Group INC | $26.63 | 2019 | |
| Biotissue Holdings INC. | $25.35 | 2019-2024 | |
| Coherus Oncology, INC. | $22.59 | 2023 | |
| Thea Pharma INC. | $19.23 | 2025 | Iyuzeh |
| Omeros Corporation | $16.38 | 2019 | |
| Glaukos Corporation | $14.39 | 2024 | Idose |
| Horizon Therapeutics Plc | $13.14 | 2023 | Tepezza |
| Quidel Corporation | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Landen Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.